Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Interstitial Lung Disease market grown in recent years?
The market size for interstitial lung disease has seen robust growth recently, projecting to expand from $1.97 billion in 2024 to $2.11 billion in 2025 with a compound annual growth rate (CAGR) of 7.2%. Factors contributing to the historical growth include increased awareness and improved diagnosis, therapies focusing on immune system modulation, respiratory rehabilitation schemes, and the integration of multidisciplinary care teams.
How is the interstitial lung disease market size expected to evolve during the forecast period?
Robust expansion is anticipated in the interstitial lung disease market in the forthcoming years, with a projection to rise to a valuation of $2.85 billion in 2029, growing at a compounded annual growth rate (CAGR) of 7.9%. The projected growth during the forecast period can be credited to advancements in precise medicine, development of new drugs, progress in regenerative medicine, and the rise of telehealth and remote monitoring. Significant upcoming trends during the forecast period encompass enhancements in imaging technology, the utilization of AI in imaging, differentiation of fibrosis subtype, and services focusing on supportive care.
Get your interstitial lung disease market report here!
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report
Which key drivers are propelling the interstitial lung disease market’s growth?
The escalating number of allergic conditions is anticipated to fuel the expansion of the interstitial lung disease sector. An allergic condition arises when the immune system excessively reacts to an allergen, often considered an innocuous substance. These allergic reactions can potentially lead to interstitial lung disease (ILD), notably hypersensitivity pneumonitis, where an allergy triggers hypersensitivity pneumonitis. For example, the National Asthma Council reported in November 2023, that there were 467 asthma-related fatalities in 2022, in Australia, which included 299 females and 168 males. This number marks a rise from the 355 deaths reported in 2021. The occurrence of allergic diseases is stimulating the skin health foods market’s growth. Hence, the escalating number of allergic conditions is pushing the growth of the interstitial lung disease industry. The prevalence of autoimmune diseases is seen to be on an upsurge and is anticipated to drive the expansion of the interstitial lung disease sector. Autoimmune diseases relate to health conditions where the immune system mistakenly attacks the body’s own healthy cells and tissues. An increase in this medical condition is contributing to the interstitial lung disease market by escalating the demand for ILD-oriented healthcare services, stimulating research and development, and propelling advancements in therapies and patient care. In September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research center, predicted that worldwide cases of rheumatoid arthritis would rise to 31.7 million by 2050, indicating a considerable increase in cases during this period. Hence, the growing number of autoimmune diseases is fuelling the growth in the interstitial lung disease industry.
What are the market segments in the interstitial lung disease industry?
The interstitial lung disease market covered in this report is segmented –
1) By Drug Type: Oral Corticosteroids, Immune Suppressing, Anti-Fibrotic Medication, Other Drugs
2) By Disease Type: Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonitis, Hypersensitivity Pneumonitis, Cryptogenic Organizing Pneumonia (COP), Sarcoidosis, Acute Interstitial Pneumonitis
3) By Application: Adults, Children
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Oral Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immune Suppressing: Azathioprine, Methotrexate, Mycophenolate Mofetil
3) By Anti-Fibrotic Medication: Pirfenidone, Nintedanib
4) By Other Drugs: Antioxidants, Anticoagulants, Other Novel Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13019&type=smp
Which leading companies are shaping the growth of the interstitial lung disease market?
Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.
What key trends are currently impacting the interstitial lung disease market’s development?
Key players in the interstitial lung disease market are placing emphasis on introducing innovative treatments for various interstitial lung disorders such as idiopathic pulmonary fibrosis (IPF). IPF is a long-term, progressively worsening lung condition characterized by scarred lung tissue, resulting in breathing problems and a decline in oxygen transfer. For example, in February 2024, the German biopharmaceutical firm C.H. Boehringer Sohn AG & Co. KG secured FDA approval for their BI 1015550 Therapy for IPF treatment. BI 1015550 is a novel oral therapy that impairs the functioning of phosphodiesterase 4B (PDE4B), boasting anti-scarring and anti-inflammatory effects designed to decelerate the deterioration of lung function in IPF patients.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13019
Which geographic areas are influencing the growth of the interstitial lung disease market?
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Respiratory Disease Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report
Anesthesia And Respiratory Devices Global Market Report 2024
Respiratory Protection Equipment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
